Drug intelligence / Profile preview

ENNO-01

Development stage: Preclinical
Lead developer: Ennovate Pharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Parenteral

Overview

ENNO-01 is a preclinical-stage bispecific antibody being developed by Ennovate Pharma for the treatment of refractory and non-responder patients with inflammatory diseases. Co-founded by Enable Medicine and General Inception, Ennovate Pharma utilizes AI/ML algorithms and single-cell spatial biology data to identify novel biomarkers and therapeutic targets. ENNO-01 is designed to target the interleukin-1 receptor (IL1R) pathway through two internally coded components, EV01 and EV03. By anchoring on the IL1R pathway, the bispecific biologic aims to address the unmet needs of patients who do not respond to current cytokine-based standard-of-care treatments.

Targets

IL-1R (Interleukin-1 receptor type 1 (IL-1R1))EV01}

Beyond the preview

Go deeper on ENNO-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENNO-01.

Explore the full profile